Table 1.
Univariate and multivariate analysis of prognostic factors in patients with gastric cancer
| Clinicopathological feature | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age (years) | ||||||
| ≤ 60 | 1 | 1 | ||||
| > 60 | 1.62 | 1.16–2.25 | 0.005 | 1.63 | 1.15–2.31 | 0.007 |
| Gender | ||||||
| Male | 1 | |||||
| Female | 1.01 | 0.73–1.40 | 0.967 | |||
| BMI | ||||||
| ≤ 24 kg/m2 | 1 | |||||
| > 24 kg/m2 | 0.77 | 0.52–1.13 | 0.175 | |||
| Tumor location | ||||||
| Upper third | 1 | |||||
| Middle third | 0.53 | 0.29–0.98 | 0.041 | |||
| Lower third | 0.47 | 0.31–0.71 | < 0.001 | |||
| Two-thirds or more | 0.76 | 0.27–2.15 | 0.600 | |||
| Gastrectomy | ||||||
| Distal | 1 | |||||
| Total | 1.57 | 1.10–2.23 | 0.013 | |||
| Proximal | NA | |||||
| Tumor size | ||||||
| ≤ 5 cm | 1 | |||||
| > 5 cm | 2.60 | 1.90–3.54 | < 0.001 | |||
| Histologic type | ||||||
| Differentiated | 1 | |||||
| Undifferentiated | 1.29 | 0.95–1.76 | 0.106 | |||
| Perineural invasion | ||||||
| Absence | 1 | |||||
| Presence | 2.73 | 2.00–3.72 | < 0.001 | |||
| Lymphovascular invasion | ||||||
| Absence | 1 | |||||
| Presence | 2.78 | 2.02–3.83 | < 0.001 | |||
| T category | ||||||
| T1 | 1 | 1 | ||||
| T2 | 4.30 | 1.56–11.83 | 0.005 | 3.04 | 1.08–8.57 | 0.036 |
| T3 | 2.04 | 0.25–16.92 | 0.510 | 1.69 | 0.20–14.50 | 0.633 |
| T4a | 15.79 | 6.97–35.76 | < 0.001 | 8.22 | 3.26–20.75 | < 0.001 |
| T4b | 28.21 | 9.78–81.36 | < 0.001 | 13.05 | 3.98–42.82 | < 0.001 |
| N category | ||||||
| N0 | 1 | 1 | ||||
| N1 | 3.22 | 1.76–5.90 | < 0.001 | 1.70 | 0.88–3.26 | 0.112 |
| N2 | 4.71 | 2.75–8.05 | < 0.001 | 2.09 | 1.15–3.81 | 0.016 |
| N3a | 11.35 | 6.82–18.89 | < 0.001 | 5.38 | 3.00–9.65 | < 0.001 |
| N3b | 24.19 | 13.27–44.07 | < 0.001 | 11.01 | 5.50–22.04 | < 0.001 |
| Chemotherapy | ||||||
| No | 1 | 1 | ||||
| Yes | 1.58 | 1.12–2.22 | 0.009 | 0.70 | 0.48–1.01 | 0.059 |
| Number of lymph nodes retrieved | ||||||
| ≤ 15 | 1 | 1 | ||||
| 16–29 | 0.75 | 0.50–1.13 | 0.169 | 0.46 | 0.30–0.70 | < 0.001 |
| ≥ 30 | 1.36 | 0.88–2.11 | 0.166 | 0.52 | 0.32–0.84 | 0.008 |
| PI | ||||||
| 0 | 1 | |||||
| 1 | 1.54 | 0.96–2.49 | 0.075 | |||
| PNI | ||||||
| < 49.5 | 1 | |||||
| ≥ 49.5 | 0.40 | 0.27–0.59 | < 0.001 | |||
| Fibrinogen | ||||||
| < 397 ng/dl | 1 | |||||
| ≥ 397 ng/dl | 2.06 | 1.51–2.81 | < 0.001 | |||
| NLR | ||||||
| < 2.5 | 1 | 1 | ||||
| ≥ 2.5 | 1.69 | 1.24–2.31 | 0.001 | 0.70 | 0.48–1.01 | 0.059 |
| PLR | ||||||
| < 154 | 1 | 1 | ||||
| ≥ 154 | 2.21 | 1.62–3.01 | < 0.001 | 1.70 | 1.20–2.42 | 0.003 |
| SII | ||||||
| < 556 | 1 | |||||
| ≥ 556 | 1.94 | 1.43–2.64 | < 0.001 | |||
| GPS | ||||||
| 0 | 1 | |||||
| 1 | 1.76 | 1.24–2.49 | 0.002 | |||
| 2 | 1.89 | 1.04–3.43 | 0.037 | |||
| mGPS | ||||||
| 0 | 1 | |||||
| 1 | 1.53 | 0.68–3.46 | 0.307 | |||
| 2 | 1.66 | 0.92–3.00 | 0.091 | |||
| CRP/Alb | ||||||
| < 0.05 | 1 | |||||
| ≥ 0.05 | 1.91 | 1.40–2.60 | < 0.001 | |||
| CEA | ||||||
| ≤ 5 ng/mL | 1 | |||||
| > 5 ng/mL | 1.76 | 1.16–2.68 | 0.008 | |||
HR Hazard ratios, CI Confidence interval, BMI Body mass index, PNI Prognostic nutritional index, PI Prognostic index, GPS Glasgow Prognostic Score, mGPS Modified Glasgow Prognostic Score, NLR Neutrophil-lymphocyte ratio, PLR Platelet-lymphocyte ratio, CRP/Alb C-reactive protein/albumin, SII Systemic immune-inflammatory index